SCHEMBL23167399

SCHEMBL23167399

O=C(Nc1ccc(C(F)(F)F)cc1)Nc1c[nH]c2cc(F)c(Br)cc12

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ STING1 Q86WV6 8/20 0.64
▸ EPHX2 P34913 1/20 0.50
▸ CA12 O43570 2/20 0.47
▸ CA1 P00915 2/20 0.47
▸ CA2 P00918 2/20 0.47
▸ CA9 Q16790 2/20 0.47
▸ MTOR P42345 1/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ MAPT P10636 2/20 0.45
▸ HTT P42858 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ TRPV1 Q8NER1 1/20 0.45
▸ GOT1 P17174 1/20 0.44
▸ BRAF P15056 1/20 0.44
▸ GRIK1 P39086 1/20 0.44
▸ BAZ1A Q9NRL2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23167888 0.91 STING1 (0.52) STING1EPHX2CA12CA1CA2
SCHEMBL30885419 0.86 STING1 (0.47) STING1MEN1KMT2AMAPTHTT
SCHEMBL23167133 0.84 STING1 (0.70) STING1EPHX2MTORMEN1KMT2A
SCHEMBL22803837 0.83 STING1 (0.77) STING1EPHX2MTORMEN1KMT2A
SCHEMBL30386673 0.82 STING1 (0.72) STING1EPHX2MTORMEN1KMT2A
SCHEMBL28991332 0.82 STING1 (0.72) STING1EPHX2MTORMEN1KMT2A
SCHEMBL23207929 0.82 STING1 (0.41) STING1EPHX2CA12CA1CA2
SCHEMBL30885443 0.81 STING1 (0.47) STING1MEN1KMT2AMAPTHTT
SCHEMBL23167140 0.81 STING1 (0.56) STING1EPHX2MTORMEN1KMT2A
SCHEMBL23207917 0.80 STING1 (0.65) STING1EPHX2CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002320-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-01-05 — — US disclosed
WO-2021067801-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2021-04-08 — — WO disclosed
WO-2021067801-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2021-04-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002320-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 STING1 1/4885EPHX2 730/4885CA12 3456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback